Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 2/3 1

Status

Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Conditions

Melanoma 37Carcinoma, Non-Small-Cell Lung 10Thyroid Neoplasms 9Neoplasms 9Colorectal Neoplasms 9Thyroid Carcinoma, Anaplastic 8Neoplasm Metastasis 6Multiple Myeloma 5Glioma 5Pancreatic Neoplasms 4Brain Neoplasms 4Thyroid Cancer, Papillary 3Recurrence 3Prostatic Neoplasms 3Neurofibromatosis 1 3Lung Neoplasms 3Hematologic Neoplasms 3Ameloblastoma 3Skin Neoplasms 2Rectal Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neurofibroma, Plexiform 2Myelodysplastic Syndromes 2Meningioma 2Lymphoma, Non-Hodgkin 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Colonic Neoplasms 2Breast Neoplasms 2Astrocytoma 2

Interventions

dabrafenib 4trametinib 3Tetracycline 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Ameloblastoma × trametinib × Clear all
NCT06819605 2025-02-11

NETCAM-RCT

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

Phase 2/3 Not yet recruiting
46 enrolled

Ameloblastoma

NCT06653517 2024-10-22

NETCAM

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

Phase 2 Recruiting
12 enrolled

Ameloblastoma

NCT02367859 2024-01-30

Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma

Stanford University

Phase 2 Completed
1 enrolled 5 charts

Ameloblastoma, Adamantinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡